GLMD (Galmed Pharmaceuticals Ltd.) Wutah bathi EPS kuartalan

Logo korporat perusahaan Galmed Pharma (GLMD)

Price action depends on biological data and the availability of R&D capital rather than economic cycles. Galmed Pharmaceuticals (GLMD) bases its business on combating liver fibrosis via small molecules, utilizing optimized supplies of biochemical raw materials. The quarterly EPS growth rate demonstrates the issuer's real economics, with the value of 43.80 serving as the current indicator for this metric.

Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan galmedpharma.com (GLMD): kanggo periode 04.07.2022 - 10.09.2026

GLMD (Galmed Pharmaceuticals Ltd.): rincian analitis lan laporan miturut indikator

- rega saham lan konsensus proyeksi valuasi:
Pambiji fundamental:Galmed Pharmaceuticals
Barang unggulan galmedpharma.com

This indicator calculates the quarterly dynamics of net profit per share, reflecting capital management efficiency and the business's ability to generate value. For Galmed Pharmaceuticals (GLMD), which is currently in the clinical trial stage without stable revenue, the quarterly EPS growth rate serves as a marker of financial stability and the cash burn rate prior to drug commercialization.